Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $7.18
Previous CloseN/A
Volume1.36M
Average Volume (3M)4.07M
Market Cap
$1.57B
Enterprise Value$908.71M
Total Cash (Recent Filing)$238.45M
Total Debt (Recent Filing)$206.64M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 30, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding240,982,830
10 Day Avg. Volume3,287,099
30 Day Avg. Volume4,067,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda-28.30
Forecast
1Y Price Target
$11.40Price Target Upside77.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Market StrategyThe prescription composition shift toward higher refill rates provides a more reliable predictor of revenue sustainability.
Product DifferentiationIbsrela remains the only non-secretagogue on the market, likely making it the preferred second-line agent and appealing to a large number of refractory patients.
Product SalesThe company reported 84% YoY growth for IBSRELA US net sales revenue for 2Q25, a point which is believed to be cultivated over the coming quarters based on growth from new prescriptions, new patient starts, and expanded depth among existing writers for both new prescriptions and refills.
Revenue GrowthArdelyx delivered a top-line beat with total revenue driven by strong Ibsrela performance and solid Xphozah execution.
Bears Say
Insurance CoverageMedicare Part D no longer covers XPHOZAH and oral phosphate binders from January 1, 2025.
Revenue ForecastA small sequential retracement in overall Xphozah revenue is expected from the first quarter to the second quarter, with growth likely returning in the third quarter.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $7.18 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.57B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Aug 04, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.052.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.06.
How many shares outstanding does Ardelyx have?
Ardelyx has 240,982,830 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went up 16.856%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.40 (77.57% Upside)
$11.40 (77.57% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 920.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $272.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.21%
12-Months-Change
Fundamentals
Return on Equity
-39.36%
Trailing 12-Months
Asset Growth
35.89%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected positive momentum with strong revenue growth, particularly for IBSRELA and XPHOZAH, despite some challenges such as the net loss and the departure of the CFO. The company appears well-positioned for continued growth.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$11.40
▲(77.57% Upside)
Technical Analysis
Celldex
―
MiMedx Group
―
Ocular Therapeutix
―
Aurinia Pharmaceuticals
―
Liquidia Technologies
―
Ownership Overview
3.36% Insiders
20.28% Mutual Funds
6.49% Other Institutional Investors
57.98% Public Companies and Individual Investors